Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).

Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance). J Clin Oncol. 2017 Apr 01; 35(10):1061-1069.

View in: PubMed

subject areas

Aged
Androstadienes
Antineoplastic Combined Chemotherapy Protocols
Aromatase Inhibitors
Breast Neoplasms
Clinical Decision-Making
Female
Follow-Up Studies
Humans
Ki-67 Antigen
Middle Aged
Mitotic Index
Neoadjuvant Therapy
Neoplasm Metastasis
Neoplasm Recurrence, Local
Neoplasm Staging
Nitriles
Predictive Value of Tests
Prognosis
Proportional Hazards Models
Receptors, Estrogen
Receptors, Progesterone
Survival Rate
Transcriptome
Triazoles

authors with profiles

Kelly J. Hunt